P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Eitemau Tebyg

• Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome
  gan: Kristina Pavlovic, et al.
  Cyhoeddwyd: (2024-05-01)
• Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression
  gan: Xiaomin Zhang, et al.
  Cyhoeddwyd: (2025-07-01)
• CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse
  gan: Søren Helweg Dam, et al.
  Cyhoeddwyd: (2026-02-01)
• Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
  gan: Audrey Grain, et al.
  Cyhoeddwyd: (2023-01-01)
• Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALLResearch in context
  gan: Berta González-Martínez, et al.
  Cyhoeddwyd: (2025-08-01)